ArticleSurgery2008
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling.
Article in Surgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 75 citations in OpenAlex.
- Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation.Molecular medicine (Cambridge, Mass.) · 2026Review
- CD47 is required for mesenchymal progenitor proliferation and fracture repair.Bone research · 2025Article
- Smooth muscle cell-specific CD47 deletion suppresses atherosclerosis.Life sciences · 2025Article
- CD47: an immunoregulatory nexus in liver and gastrointestinal disorders.eGastroenterology · 2025Review
- Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity.Cell death and differentiation · 2024Review
- Airway epithelial CD47 plays a critical role in inducing influenza virus-mediated bacterial super-infection.Nature communications · 2024Article
- CD47 is Required for Mesenchymal Progenitor Proliferation and Fracture Repair.Research square · 2024Article
- CD47 is Required for Mesenchymal Progenitor Proliferation and Fracture Repair.bioRxiv : the preprint server for biology · 2024Article
- Tolerating CD47.Clinical and translational medicine · 2024Review
- Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Interleukin-27 in liver xenotransplantation: A rational target to mitigate ischemia reperfusion injury and increase xenograft survival.Transplantation reviews (Orlando, Fla.) · 2022Review
- The effects of cell surface CD47 downregulation on ischaemia-reperfusion injury during pig liver transplantation.International journal of experimental pathology · 2021Article
- Functions of Thrombospondin-1 in the Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors.Journal of immunology research · 2021Article
- Thrombospondin-1 in maladaptive aging responses: a concept whose time has come.American journal of physiology. Cell physiology · 2020Review
- The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.Pediatric nephrology (Berlin, Germany) · 2019Review
- Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo.Nature communications · 2019Article
- Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- CD47 Deficiency Attenuates Isoproterenol-Induced Cardiac Remodeling in Mice.Oxidative medicine and cellular longevity · 2019Article
- CD47 blockade reduces ischemia/reperfusion injury in donation after cardiac death rat kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIschemia-reperfusion (I/R) injury remains a primary complication of transplant surgery, accounting for about 80% of liver transplant failures, and is a major source of morbidity in other pathologic conditions. Activation of endothelium and inflammatory cell recruitment are central to the initiation and promulgation of I/R injury, which can be limited by the bioactive gas nitric oxide (NO). The discovery that thrombsospondin-1 (TSP1), via CD47, limits NO signaling in vascular cells and ischemic injuries in vivo suggested that I/R injury could be another important target of this signaling pathway.
methodsWild-type, TSP1-null, and CD47-null mice underwent liver I/R injury. Wild-type animals were pretreated with CD47 or control antibodies before liver I/R injury. Tissue perfusion via laser Doppler imaging, serum enzymes, histology, and immunohistology were assessed.
resultsTSP1-null and CD47-null mice subjected to subtotal liver I/R injury showed improved perfusion relative to wild-type mice. Null mice subjected to liver I/R had decreased liver enzyme release and less histologic evidence of injury. Elevated TSP1 expression in liver tissue after I/R injury suggested that preventing its interaction with CD47 could be protective. Thus, pretreatment of wild-type mice using a blocking CD47 antibody improved recovery of tissue perfusion and preserved liver integrity after I/R injury.
conclusionsTissue survival and perfusion after liver I/R injury are limited by TSP1 and CD47. Targeting CD47 before I/R injury enhances tissue survival and perfusion in a model of liver I/R injury and suggests therapeutics for enhancing organ survival in transplantation surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.